Ariad Pharmaceuticals, Inc. (ARIA) Announces Support of Patients With Resistant or Intolerant CML Through Its Donation to Chronic Disease Fund
4/2/2013 10:04:21 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it had made a donation to the Chronic Disease Fund (CDF) in support of patients with chronic myeloid leukemia (CML) who are resistant or intolerant to prior therapy. CDF is an independent non-profit charitable organization that helps eligible patients with chronic diseases, cancer and other life-altering conditions obtain the life-saving medications they need. Through ARIAD’s contribution, the organization will provide financial assistance to eligible patients with resistant or intolerant CML who require help paying their out-of-pocket expenses, including co-pays or co-insurance. CDF will determine the distribution of these funds and patient eligibility.